The use of chloroquine and D-penicillamine in the treatment of rheumatoid arthritis.
Muirden
K D
KD
D019867:Anti-Glomerular Basement Membrane Disease / Q000139:chemically induced; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002216:Captopril / Q000627:therapeutic use; D002738:Chloroquine / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D005921:Glomerulonephritis / Q000139:chemically induced; D006801:Humans; D006886:Hydroxychloroquine / Q000009:adverse effects / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced; D009157:Myasthenia Gravis / Q000139:chemically induced; D009220:Myositis / Q000139:chemically induced; D010392:Pemphigus / Q000139:chemically induced; D010396:Penicillamine / Q000009:adverse effects / Q000627:therapeutic use*; D011746:Pyrithioxin / Q000627:therapeutic use; D012460:Sulfasalazine / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced
D012460:Sulfasalazine; D006886:Hydroxychloroquine; D002738:Chloroquine; D002216:Captopril; D011746:Pyrithioxin; D010396:Penicillamine